Cargando…

Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine

Apolipoprotein E4 (Apo E4) is the major genetic risk factor in the causation of Alzheimer's disease (AD). In this study we utilize virtual screening of the world's largest traditional Chinese medicine (TCM) database and investigate potential compounds for the inhibition of ApoE4. We presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hung-Jin, Chen, Hsin-Yi, Lee, Cheng-Chun, Chen, Calvin Yu-Chian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055423/
https://www.ncbi.nlm.nih.gov/pubmed/24967370
http://dx.doi.org/10.1155/2014/452625
_version_ 1782320657339514880
author Huang, Hung-Jin
Chen, Hsin-Yi
Lee, Cheng-Chun
Chen, Calvin Yu-Chian
author_facet Huang, Hung-Jin
Chen, Hsin-Yi
Lee, Cheng-Chun
Chen, Calvin Yu-Chian
author_sort Huang, Hung-Jin
collection PubMed
description Apolipoprotein E4 (Apo E4) is the major genetic risk factor in the causation of Alzheimer's disease (AD). In this study we utilize virtual screening of the world's largest traditional Chinese medicine (TCM) database and investigate potential compounds for the inhibition of ApoE4. We present the top three TCM candidates: Solapalmitine, Isodesacetyluvaricin, and Budmunchiamine L5 for further investigation. Dynamics analysis and molecular dynamics (MD) simulation were used to simulate protein-ligand complexes for observing the interactions and protein variations. Budmunchiamine L5 did not have the highest score from virtual screening; however, the dynamics pose is similar to the initial docking pose after MD simulation. Trajectory analysis reveals that Budmunchiamine L5 was stable over all simulation times. The migration distance of Budmunchiamine L5 illustrates that docked ligands are not variable from the initial docked site. Interestingly, Arg158 was observed to form H-bonds with Budmunchiamine L5 in the docking pose and MD snapshot, which indicates that the TCM compounds could stably bind to ApoE4. Our results show that Budmunchiamine L5 has good absorption, blood brain barrier (BBB) penetration, and less toxicity according to absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction and could, therefore, be safely used for developing novel ApoE4 inhibitors.
format Online
Article
Text
id pubmed-4055423
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40554232014-06-25 Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine Huang, Hung-Jin Chen, Hsin-Yi Lee, Cheng-Chun Chen, Calvin Yu-Chian Biomed Res Int Research Article Apolipoprotein E4 (Apo E4) is the major genetic risk factor in the causation of Alzheimer's disease (AD). In this study we utilize virtual screening of the world's largest traditional Chinese medicine (TCM) database and investigate potential compounds for the inhibition of ApoE4. We present the top three TCM candidates: Solapalmitine, Isodesacetyluvaricin, and Budmunchiamine L5 for further investigation. Dynamics analysis and molecular dynamics (MD) simulation were used to simulate protein-ligand complexes for observing the interactions and protein variations. Budmunchiamine L5 did not have the highest score from virtual screening; however, the dynamics pose is similar to the initial docking pose after MD simulation. Trajectory analysis reveals that Budmunchiamine L5 was stable over all simulation times. The migration distance of Budmunchiamine L5 illustrates that docked ligands are not variable from the initial docked site. Interestingly, Arg158 was observed to form H-bonds with Budmunchiamine L5 in the docking pose and MD snapshot, which indicates that the TCM compounds could stably bind to ApoE4. Our results show that Budmunchiamine L5 has good absorption, blood brain barrier (BBB) penetration, and less toxicity according to absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction and could, therefore, be safely used for developing novel ApoE4 inhibitors. Hindawi Publishing Corporation 2014 2014-05-21 /pmc/articles/PMC4055423/ /pubmed/24967370 http://dx.doi.org/10.1155/2014/452625 Text en Copyright © 2014 Hung-Jin Huang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Huang, Hung-Jin
Chen, Hsin-Yi
Lee, Cheng-Chun
Chen, Calvin Yu-Chian
Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine
title Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine
title_full Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine
title_fullStr Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine
title_full_unstemmed Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine
title_short Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine
title_sort computational design of apolipoprotein e4 inhibitors for alzheimer's disease therapy from traditional chinese medicine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055423/
https://www.ncbi.nlm.nih.gov/pubmed/24967370
http://dx.doi.org/10.1155/2014/452625
work_keys_str_mv AT huanghungjin computationaldesignofapolipoproteine4inhibitorsforalzheimersdiseasetherapyfromtraditionalchinesemedicine
AT chenhsinyi computationaldesignofapolipoproteine4inhibitorsforalzheimersdiseasetherapyfromtraditionalchinesemedicine
AT leechengchun computationaldesignofapolipoproteine4inhibitorsforalzheimersdiseasetherapyfromtraditionalchinesemedicine
AT chencalvinyuchian computationaldesignofapolipoproteine4inhibitorsforalzheimersdiseasetherapyfromtraditionalchinesemedicine